Peapod Lane Capital LLC Purchases 344,437 Shares of OraSure Technologies, Inc. $OSUR

Peapod Lane Capital LLC increased its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 51.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,018,470 shares of the medical instruments supplier’s stock after purchasing an additional 344,437 shares during the quarter. OraSure Technologies accounts for approximately 2.1% of Peapod Lane Capital LLC’s investment portfolio, making the stock its 17th largest position. Peapod Lane Capital LLC’s holdings in OraSure Technologies were worth $2,465,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of OSUR. Prudential Financial Inc. bought a new stake in OraSure Technologies during the second quarter worth about $31,000. Amundi bought a new stake in OraSure Technologies during the first quarter worth about $47,000. SG Americas Securities LLC lifted its position in OraSure Technologies by 77.7% during the fourth quarter. SG Americas Securities LLC now owns 19,748 shares of the medical instruments supplier’s stock worth $48,000 after purchasing an additional 8,632 shares during the period. BNP Paribas Financial Markets lifted its position in OraSure Technologies by 102.2% during the third quarter. BNP Paribas Financial Markets now owns 15,275 shares of the medical instruments supplier’s stock worth $49,000 after purchasing an additional 7,720 shares during the period. Finally, Private Advisor Group LLC bought a new stake in OraSure Technologies during the third quarter worth about $57,000. Institutional investors own 93.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of OraSure Technologies in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, OraSure Technologies currently has an average rating of “Reduce” and a consensus target price of $3.00.

OraSure Technologies Stock Down 2.2%

OSUR opened at $3.05 on Friday. OraSure Technologies, Inc. has a twelve month low of $2.08 and a twelve month high of $3.82. The company has a 50-day simple moving average of $3.02 and a 200 day simple moving average of $2.76. The stock has a market capitalization of $219.51 million, a price-to-earnings ratio of -3.28 and a beta of 0.85.

OraSure Technologies (NASDAQ:OSUR) last posted its earnings results on Wednesday, February 25th. The medical instruments supplier reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). The company had revenue of $26.76 million during the quarter, compared to the consensus estimate of $26.44 million. OraSure Technologies had a negative return on equity of 16.45% and a negative net margin of 59.76%.

Insider Transactions at OraSure Technologies

In related news, CEO Manner Carrie Eglinton bought 32,300 shares of the company’s stock in a transaction dated Friday, March 20th. The stock was purchased at an average price of $2.93 per share, with a total value of $94,639.00. Following the completion of the acquisition, the chief executive officer owned 2,190,874 shares of the company’s stock, valued at $6,419,260.82. The trade was a 1.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kenneth J. Mcgrath bought 32,300 shares of the company’s stock in a transaction dated Friday, March 20th. The stock was bought at an average cost of $2.93 per share, with a total value of $94,639.00. Following the acquisition, the chief financial officer directly owned 589,562 shares of the company’s stock, valued at approximately $1,727,416.66. The trade was a 5.80% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought 108,643 shares of company stock valued at $321,407 in the last three months. Company insiders own 3.90% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.